- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Emerging Brain PET System
Offering dedicated PET imaging of the brain, the compact NeuroLF system may facilitate patient comfort while enabling detection and monitoring of brain tumors, epilepsy, and neurodegenerative diseases such as Alzheimer’s disease.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the NeuroLF system, which offers dedicated positron emission tomography (PET) imaging of the brain.
In light of the recent FDA approval of another disease-modifying therapy (Kisunla, Lilly) for Alzheimer’s disease, which reportedly accounts for approximately 70 percent of dementia cases for patients over 60 years of age, the FDA clearance of the NeuroLF system for monitoring and detection of neurological conditions is particularly timely, according to Positrigo, the developer of the NeuroLF device.
The newly FDA-cleared NeuroLF PET imaging system, which enables detection and monitoring of conditions ranging from epilepsy to Alzheimer's disease, offers a compact design that facilitates patient comfort, according to Postrigo, the developer of the device. (Image courtesy of Positrigo.)
Positrigo noted the PET imaging system also facilitates diagnosis of brain tumors, epilepsy, and neurodegenerative conditions such as Parkinson’s disease.
While other PET systems involve bulky devices with significant maintenance costs, Positrigo emphasized the compact design of the NeuroLF system, which allows functional point-of-care brain PET scans with patients in a seated position.
"It is not the first device of its kind which receives market clearance in the (United States) but we believe that our patient-centric and customer-driven design and development efforts over the last couple of years brought us into the pole position to offer the best imaging solution to address the increased demand of brain PET scans," noted Jannis Fischer, Ph.D., the co-founder and CEO of Positrigo.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
